CAMBRIDGE, Mass. — Gensaic, Inc., a metabolic health biotechnology company combining AI-guided protein evolution with multi-targeted siRNA to develop precision medicines, said it has appointed Nathan Higginson-Scott, PhD, as Chief Research and Development Officer.
The newly created role expands Gensaic’s executive leadership as the company advances its platform from foundational innovation toward therapeutic product development. Higginson-Scott will oversee scientific strategy and R&D programs, with a focus on translating Gensaic’s delivery engine into clinically impactful therapies.
“What drew me to Gensaic is the broad applicability, and ambition, of its AI-powered platform in precision medicine with an ability to deliver potent and durable oligonucleotide-based therapeutics to the right tissues, cell types, and even sub-cellular locations to address complex disease biology,” Higginson-Scott said. “The opportunity to help evolve a mature, solid foundation into a robust clinical pipeline, alongside a team that is both ambitious and pragmatic, is rare and deeply compelling.”
Higginson-Scott brings extensive experience in biologics innovation, platform development, and advancing early science into clinical-stage programs. Most recently, he served as Chief Technology Officer and Senior Vice President of Drug Creation at Seismic Therapeutic, where he led work across protein engineering, structural biology, CMC, and machine-learning-enabled immunology drug discovery. During his tenure, two autoimmune disease biologics advanced from inception into the clinic.
Previously, Higginson-Scott was Vice President of Biotherapeutics at Pandion Therapeutics, where he contributed to the company’s growth from seed stage through major financings, a public offering, clinical progression, and its acquisition by Merck in 2021. Earlier in his career at Pfizer, he co-invented a proprietary bispecific platform, led antibody optimization initiatives, and advanced multiple technology development and drug discovery programs from target identification through IND filing across several therapeutic areas.
Higginson-Scott earned a doctorate in molecular immunology and a master’s degree in cell and molecular biology of infectious disease from Imperial College London, and a bachelor’s degree in microbiology from the University of Kent in the United Kingdom.
“We are delighted to welcome Nathan to Gensaic at this critical juncture, as we progress our lead assets to the clinic and expand our machine-guided discovery access to additional tissues and payload architectures,” said Lavi Erisson, MD, CEO and President of Gensaic. “His deep experience in identifying clinical-ready programs, shaping portfolios, and building high-performing teams will complement Gensaic’s existing leadership and strengthen our ability to translate scientific ambition into clinical impact. His appointment marks an important milestone in our company’s evolution.”
